The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2024 | The role of alloSCT in LBCL in the era of CAR-T
Anna Czyz, MD, PhD, Wroclaw Medical University, Wroclaw, Poland, comments on the role of allogeneic stem cell transplantation (alloSCT) for the treatment of large B-cell lymphoma (LBCL) in the era of CAR T-cell therapy. Dr Czyz emphasizes that alloSCT is an excellent therapeutic option for patients who do not achieve complete remission (CR) within 3 months of CAR T-cell infusion. Due to the progress made in treating graft-versus-host disease (GvHD) and in anti-viral prophylaxis, the outcomes of patients undergoing alloSCT have substantially improved in the last decade. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
